In this issue:
LNR predicts adjuvant chemotherapy benefit in ESCC
KEYNOTE-585: No survival benefit to perioperative pembrolizumab
Mycobiome profiling may predict response to neoadjuvant immunochemotherapy
Encouraging activity for neoadjuvant immuno-chemo in locally advanced dMMR disease
Omission of nasogastric tube post-resection risks anastomotic leakage
Radiation dose escalation beneficial in select subgroups with locally advanced disease
Second-line T-DXd boosts survival in unresectable HER2-positive disease
CLDN18.2–targeting antibody–drug conjugate promising for advanced disease
High surgical conversion rate with neoadjuvant chemoradiation + immunotherapy for ESCC
First-in-class bispecific antibody-drug conjugate promising for pretreated ESCC
Please login below to download this issue (PDF)